Boehringer Ingelheim - Articles and news items

Relocating the EMA: An open letter from EFPIA and Pharma Heads of Research

Industry news / 16 May 2017 / European Federation of Pharmaceutical Industries and Associations (EFPIA)

The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines

New technology could dramatically shorten diagnosis time of stroke patients

New technology could dramatically shorten diagnosis time of stroke patients

Industry news / 11 May 2017 / Sarah Wills, Editorial Assistant

An ambitious collaboration between Brainomix, an emerging British business, and Boehringer Ingelheim, one of the world’s largest drug companies, is poised to expedite and improve treatment of stroke, the second biggest killer disease in Europe.

biosimilars

Biosimilars: the future of Pharma? An interview with Boehringer Ingelheim

Blog, Z Homepage promo / 3 May 2017 / Ivan Blanarik, Senior Vice President and Head of Therapeutic Area Biosimilars at Boehringer Ingelheim

With biosimilars expected to account for 10% of the total biologics market by 2020, we caught up with Boehringer Ingelheim’s Senior VP to find out more…

The Top 21…wealthiest pharma companies

Blog, Z Homepage promo / 6 February 2017 / Niamh Marriott, Digital Editor

Find out who made it to the top of our list of richest pharma companies…

cardiovascular death

FDA approves drug that reduces risk of cardiovascular death in diabetics

Industry news / 12 December 2016 / Niamh Louise Marriott, Digital Editor

It significantly reduced the risk of (the combined primary endpoint) cardiovascular death, non-fatal heart attack or non-fatal stroke by 14% versus placebo…

Boehringer Ingelheim’s bevacizumab biosimilar demonstrates bioequivalence

Industry news / 21 November 2016 / Niamh Louise Marriott, Digital Content Producer

BI 695502, a bevacizumab biosimilar candidate to Avastin, is a monoclonal antibody that may slow or stop the growth of certain tumour types by preventing…

Reduced risk of NSCLC death seen in Boehringer Ingelheim’s head-to-head trial

Industry news / 12 October 2016 / Niamh Louise Marriott, Digital Content Producer

The trial investigated overall survival and the reduction in risk of death (14%) was observed for patients treated with afatinib versus gefitinib…

Boehringer Ingelheim and ViraTherapeutics collaborate to boost immune-oncology pipeline

Industry news / 29 September 2016 / Niamh Louise Marriott, Digital Content Producer

Under the terms of the collaboration, Boehringer Ingelheim receives the right to acquire ViraTherapeutics after conclusion of Phase I clinical development…

Orphan drug designation granted to Boehringer Ingelheim’s systemic sclerosis drug

Industry news / 13 September 2016 / Niamh Louise Marriott, Digital Content Producer

Senscis is specifically evaluating nintedanib to understand the disease process and potential benefit of the compound to treat SSc-ILD…

Lilly and Boehringer Ingelheim take on metastatic breast cancer

Industry news / 13 July 2016 / Victoria White, Digital Content Producer

Lilly and Boehringer Ingelheim are to collaborate on a Phase Ib study of abemaciclib and BI 836845 in patients with HR+, HER2- metastatic breast cancer…

First patient enrolled in IPF biomarker study of Ofev

Industry news / 30 June 2016 / Victoria White, Digital Content Producer

INMARK is a study investigating the effect of Ofev (nintedanib) on changes in specific blood biomarkers in patients with idiopathic pulmonary fibrosis…

Sanofi and Boehringer Ingelheim reach next step in business swap

Industry news / 27 June 2016 / Victoria White, Digital Content Producer

Sanofi and Boehringer Ingelheim have signed contracts to secure the exchange of Sanofi’s Merial and Boehringer Ingelheim’s consumer healthcare business…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+